Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apolipoprotein E Receptor Type II (ApoER2), also known as LRP8, is a member of the low-density lipoprotein receptor (LDLR) family. It is a type I transmembrane protein that functions in both endocytosis and signal transduction, particularly in the Reelin pathway, which is essential for neuronal migration during brain development and synaptic plasticity. ApoER2 also mediates the internalization of apolipoprotein E-containing lipoproteins. Dysfunction or reduced expression of ApoER2 is associated with impaired brain development, deficits in learning/memory, and increased risk of neurodegenerative diseases like Alzheimer’s disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apolipoprotein E Receptor Type II (ApoER2).